Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 11/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 7/20 | 0.36 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.33 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17068671 | 0.83 | HPGD (0.37) | LTB4RLTB4R2HPGDGLA | |
| SCHEMBL17068618 | 0.81 | HPGD (0.35) | LTB4RLTB4R2CYSLTR1CYSLTR2HPGD | |
| SCHEMBL17068461 | 0.79 | — | — | |
| SCHEMBL17068677 | 0.79 | CYP2C9 (0.34) | — | |
| SCHEMBL18006758 | 0.78 | KCNQ3 (0.32) | LTB4RLTB4R2HPGD | |
| SCHEMBL17068611 | 0.77 | HTR2A (0.34) | GLA | |
| SCHEMBL17068608 | 0.77 | LTB4R (0.34) | LTB4RLTB4R2 | |
| SCHEMBL17068592 | 0.76 | KDM1A (0.31) | — | |
| SCHEMBL17068561 | 0.76 | TOP2A (0.35) | HPGD | |
| SCHEMBL17068598 | 0.74 | LTB4R (0.34) | LTB4RLTB4R2CYSLTR1CYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9523038-B2 | Dihydropyran compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-12-20 | — | — | US | disclosed |
| US-9523038-B2 | Dihydropyran compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-12-20 | — | — | US | disclosed |
| US-20150252264-A1 | DIHYDROPYRAN COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2015-09-10 | — | — | US | disclosed |
| US-20150252264-A1 | DIHYDROPYRAN COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252264-A1 | DIHYDROPYRAN COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | DRD1, CNKSR1, DRG1 | LTB4R 827/4885LTB4R2 610/4885CYSLTR1 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.